AnaptysBio, Inc.

ANAB

US0327241065

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-02-13 pm EST			5-day change	1st Jan Change
53.08 ^USD	-3.32%		+6.74%	+9.49%

Jan. 09	AnaptysBio Moves to Dismiss GSK's Tesaro Lawsuit Over Jemperli Royalty Dispute	MT
Jan. 09	UK Stocks-Factors to watch on January 9	RE

AnaptysBio seeks partial dismissal in GSK oncology unit dispute over drug royalty

Published on 01/08/2026 at 07:07 pm EST

Reuters

Latest news about AnaptysBio, Inc.

Jan. 09	AnaptysBio Moves to Dismiss GSK's Tesaro Lawsuit Over Jemperli Royalty Dispute	MT
Jan. 09	UK Stocks-Factors to watch on January 9	RE
Jan. 08	AnaptysBio seeks partial dismissal in GSK oncology unit dispute over drug royalty	RE
Jan. 08	Anaptys files motion to dismiss Tesaro's claim of anticipatory breach of contract in ongoing litigation	RE
Jan. 08	Anaptysbio Insider Sold Shares Worth $439,200, According to a Recent SEC Filing	MT
Dec. 23	Anaptysbio Insider Sold Shares Worth $510,000, According to a Recent SEC Filing	MT
Dec. 23	Anaptysbio Insider Sold Shares Worth $500,000, According to a Recent SEC Filing	MT
Dec. 15	Vanda announces submission of biologics license application to the FDA for Imsidolimab for the treatment of generalized pustular psoriasis	RE
Nov. 28	Sector Update: Health Care Stocks Decline Friday Afternoon	MT
Nov. 28	AnaptysBio, GSK's Tesaro Unit Likely Settle Jemperli Dispute Before July, Wedbush Says	MT
Nov. 26	AnaptysBio's complaint against Tesaro for breaching agreement was publicly filed on Nov 26 - SEC filing	RE
Nov. 24	AnaptysBio Presents Opportunity Despite 'Near-Term Turbulence' Amid Legal Dispute with GSK, Wedbush Says	MT
Nov. 21	Health Care Up as Traders Seek Out Evergreen Sector -- Health Care Roundup	DJ
Nov. 21	European Equities Close Mixed in Friday Trading; Eurozone Composite PMI Continues to Expand	MT
Nov. 21	FTSE 100 Ticks Up Amid UK Retail Sales, Borrowing Data	MT

AnaptysBio, Inc. is a clinical-stage biotechnology company focused on delivering immunology therapeutics. The Company is developing immune cell modulators, including two checkpoint agonists for autoimmune and inflammatory disease: rosnilimab, its PD-1 agonist, in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis; and ANB032, its BTLA agonist, in a Phase 2b trial for the treatment of atopic dermatitis. The Company's preclinical immune cell modulator portfolio includes ANB033, an anti-CD122 antagonist antibody, and ANB101, a BDCA2 modulator antibody, for the treatment of autoimmune and inflammatory diseases. In addition, it has developed two cytokine antagonists available for out-licensing: imsidolimab, an anti-IL-36R antagonist, in Phase 3 for the treatment of generalized pustular psoriasis, or GPP, and etokimab, an anti-IL-33 antagonist for the treatment of respiratory disorders that is Phase 2/3 ready.

Employees

136

Sector

Biotechnology & Medical Research

Calendar

Mar. 04 - TD Cowen Health Care Conference

More about the company